title: Short-term safety of celocentesis for the mother and the fetus.
abstract: OBJECTIVE
  Celocentesis offers the potential for prenatal diagnosis from as early as 6 weeks of gestation. The aim of this study was to examine the short-term safety of celocentesis.
  
  
  METHODS
  Eligible for the study were pregnant women with single live fetuses at 6-10 weeks of gestation, requesting pregnancy termination for social indications. At presentation, the patients were asked if they were willing to undergo celocentesis and in those women who agreed the procedure was performed at the time of the initial scan. A second scan was carried out just before termination to measure fetal crown-rump length and heart rate.
  
  
  RESULTS
  Four hundred and forty-seven women requested termination of pregnancy and 108 of these agreed to have celocentesis. There were no significant differences between the groups in maternal age, prevalence of primigravidas, cigarette smokers, existence of uterine fibroids, the median fetal crown-rump length or the interval between the initial scan (or celocentesis) at presentation and the pregnancy termination. At the time of termination, ultrasound examination demonstrated fetal death in five (4.7%) of the celocentesis group and nine (2.7%) of the controls (odds ratio, 1.804; 95% confidence interval, 0.5912-5.504). In all other cases, there was normal fetal growth and there were no significant differences between the groups in fetal crown-rump length.
  
  
  CONCLUSIONS
  The procedure related fetal loss associated with celocentesis may be approximately 2%.
authors.affiliation: Department of Obstetrics and Gynaecology, Ioannina University Hospital, Ioannina, Greece. grmak@otenet.gr
authors.forename: G
authors.initials: G
authors.lastname: Makrydimas
authors.forename: A
authors.initials: A
authors.lastname: Kaponis
authors.forename: C
authors.initials: C
authors.lastname: Skentou
authors.forename: D
authors.initials: D
authors.lastname: Lolis
mesh_terms: D000293:Adolescent; D000328:Adult; D000649:Amniocentesis / Q000009:adverse effects / Q000379:methods*; D016009:Chi-Square Distribution; D015193:Chorionic Villi Sampling / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005313:Fetal Death / Q000517:prevention & control; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control; D011261:Pregnancy Trimester, First; D011296:Prenatal Diagnosis / Q000379:methods; D011336:Probability; D011446:Prospective Studies; D018570:Risk Assessment; D012449:Safety; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D013997:Time Factors